Led by newly-crowned 900-game winner Tim McDonald, the No. 2 Bay City Western Warriors are 35-6 with a Saginaw Valley League championship – like Dakota, who is 35-7 with a Macomb Area Conference ...

Photo Credit: Nemes Laszlo The following is a summary of “BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia,” published in the March 2025 issue ...

Venetoclax specifically binds to BCL-2, displacing apoptotic activators, which then reinitiate the apoptosis process. Sensitivity to venetoclax depends not only on BCL-2 levels but also on the ...

Total protein and RNA were extracted for western Blot analysis and quantitative polymerase chain reaction. Results and conclusions: bcl-2 specific siRNAs specifically inhibited expression of the ...

Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy.

Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax in combination with azacitidine in patients with treatment-naïve or ...

Fochon Biosciences Ltd. has identified apoptosis regulator Bcl-2 (D103E mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

In CLL, we are seeing the use of second-generation BTK inhibitors, use of BTK inhibition alongside BCL-2 inhibitors, and studies of third-generation BTK inhibitors.

Abstract. Background: The Bcl-2 inhibitor venetoclax is approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). However, ...

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic ...